晚期HIV病患者首次抗逆转录病毒治疗中的死亡率和免疫病毒学结局:抗逆转录病毒方案的不同影响
这项多中心前瞻性队列研究纳入2010至2020年间开始治疗的1594例晚期HIV病初治成人,中位CD4+ T细胞计数81个/mm3,371例(23.3%)有艾滋病定义性疾病。使用整合酶链转移抑制剂方案者3年调整死亡率3.1%,低于蛋白酶抑制剂方案的4.7%和非核苷逆转录酶抑制剂方案的7.6%(P=0.001),且病毒抑制和免疫重建更早。
要点
- 晚期HIV病患者使用整合酶链转移抑制剂方案与较低死亡风险相关(HR 0.5,95%CI 0.3-0.9)。
- 整合酶链转移抑制剂组3年调整死亡率3.1%,蛋白酶抑制剂组4.7%,非核苷逆转录酶抑制剂组7.6%(P=0.001)。
- 整合酶链转移抑制剂组患者达到病毒抑制和CD4+ T细胞计数超过350个/mm3的时间显著更早。
核心结论
- 在这项大型真实世界前瞻性队列研究中,晚期HIV病患者使用整合酶链转移抑制剂治疗观察到显著更低的死亡率、更早的病毒抑制和更早的免疫重建。
研究设计与样本
- 多中心前瞻性队列研究,纳入2010至2020年间开始治疗的1594例晚期HIV病初治成人,中位随访4.44年。
主要发现
- 整合酶链转移抑制剂方案最常见(46.9%),其次为蛋白酶抑制剂(35.7%)和非核苷逆转录酶抑制剂(17.4%)。
- 3年调整死亡率分别为整合酶链转移抑制剂组3.1%(95%CI 1.8%-4.3%)、蛋白酶抑制剂组4.7%(95%CI 2.2%-7.1%)和非核苷逆转录酶抑制剂组7.6%(95%CI 5.4%-9.7%)(P=0.001)。
- 与死亡率增加相关的因素包括年龄较大和注射吸毒史,而整合酶链转移抑制剂治疗为保护因素(HR 0.5,95%CI 0.3-0.9)。
- 倾向性评分匹配敏感性分析证实了上述结果。
- 开始整合酶链转移抑制剂的患者达到病毒抑制和CD4+ T细胞计数超过350个/mm3的时间显著更早。
关键数值与推荐
- 晚期HIV病定义为CD4+ T细胞计数<200个/mm3或存在艾滋病定义性疾病。
- 病毒学有效性定义为病毒载量≤50拷贝/mL的患者百分比。
- 免疫重建定义为CD4+ T细胞计数超过350个/mm3的患者百分比。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess the clinical and immunovirological outcomes among naive patients with advanced HIV presentation starting an antiretroviral regimen in real-life settings. METHODS: This was a multicentre, prospective cohort study. We included all treatment-naive adults with advanced HIV disease (CD4+ T cell count < 200 cells/mm3or presence of an AIDS-defining illness) who started therapy between 2010 and 2020. The main outcomes were mortality, virological effectiveness (percentage of patients with viral load of ≤50 copies/mL) and immune restoration (percentage of patients with CD4+ T cell count above 350 cells/mm3). Competing risk analysis and Cox proportional models were performed. A propensity score-matching procedure was applied to assess the impact of the antiretroviral regimen. RESULTS: We included 1594 patients with advanced HIV disease [median CD4+T cell count of 81 cells/mm3and 371 (23.3%) with AIDS-defining illness] and with a median follow-up of 4.44 years. The most common ART used was an integrase strand transfer inhibitor (InSTI) regimen (46.9%), followed by PI (35.7%) and NNRTI (17.4%), with adjusted mortality rates at 3 years of 3.1% (95% CI 1.8%-4.3%), 4.7% (95% CI 2.2%-7.1%) and 7.6% (95% CI 5.4%-9.7%) (P = 0.001), respectively. Factors associated with increased mortality included older age and history of injection drug use, whilst treatment with an InSTI regimen was a protective factor [HR 0.5 (95% CI 0.3-0.9)]. A sensitivity analysis with propensity score procedure confirms these results. Patients who started an InSTI achieved viral suppression and CD4+ T cell count above 350 cells/mm3significantly earlier. CONCLUSIONS: In this large real-life prospective cohort study, a significant lower mortality, earlier viral suppression and earlier immune reconstitution were observed among patients with advanced HIV disease treated with InSTIs.
引用
- Burgos J, Moreno-Fornés S, Reyes-Urueña J, et al. Mortality and immunovirological outcomes in patients with advanced HIV disease on their first antiretroviral treatment: differential impact of antiretroviral regimens. J Antimicrob Chemother. 2022. PMID: 36308326. doi:10.1093/jac/dkac361
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。